Skip to main content
Michael Montejo, MD, Radiation Oncology, Tampa, FL

Michael Edward Montejo MD


Moffitt Cancer

Join to View Full Profile
  • 12902 Usf Magnolia DrTampa, FL 33612

  • Phone+1 813-745-7030

  • Fax+1 813-745-8495

Dr. Montejo is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Utah Health
    University of Utah HealthResidency, Radiation Oncology, 2007 - 2011
  • Orlando Health
    Orlando HealthInternship, Internal Medicine, 2006 - 2007
  • University of South Florida College of Medicine
    University of South Florida College of MedicineClass of 2006
  • University of Miami
    University of MiamiB.S., Major in Microbiology, minor in Chemistry/Biology, Cum Laude, 1997 - 2001

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2011 - 2027
  • GA State Medical License
    GA State Medical License 2013 - 2014
  • UT State Medical License
    UT State Medical License 2007 - 2012
  • Radiation Oncology
    American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014, 2016
  • CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014, 2016
  • CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014, 2016

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations  
    Grass GD, Mills MN, Ahmed KA, Liveringhouse CL, Montejo MJ, Robinson TJ, Chavez JC, Harrison LB, Kim S, Leuk Lymphoma, 1/1/2018
  • IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma  
    Montejo, ME, Shrieve, DC, Bentz, BG, Hunt, JP, Buchmann, LO, Agarwal, N, and Hitchcock, YJ, Int J Radiat Oncol Biol Phys, 1/1/2011
  • Treatment of Intermediate Risk Prostate Cancer with I-125 Permanent Interstitial Brachytherapy Monotherapy A Review of the H Lee Moffitt Cancer Center Experience  
    Torres-Roca, JF, Cantor, AB, Shukla, S, Montejo, ME, Friedland, J, Seigne, JD, Heysek, R, Me Marco, ML, Kelley, S, and Pow-Sang, J, Urologic Oncology, 1/1/2006

Abstracts/Posters

  • Clinical Outcome and Late Toxicity following Definitive Intensity Modulated Radiotherapy for Squamous Cell Carcinoma of the Vulva
    Anupam Rishi, Madeline Rollins, Daniel Fernandez, Kamran Ahmed, Mitchel Hoffman, Mian Shahzad, Sachin Apte, Jing-Yi Chern, Hye Chon, Robert Wenham, Michael Montejo, ASTRO, 1/1/2018
  • IMRT with Simultaneous Integrated Boost (IMRT-SIB) with Concurrent Cisplatin for Advanced Squamous Cell Carcinoma of the Head and Neck
    Montejo, ME, Shrieve, DC, Bentz, BG, Hunt, JP, Buchmann, LO, Agarwal, N, and Hitchcock, YJ, American Society of Therapeutic Radiation Oncology (ASTRO), 1/1/2009
  • Treatment of Intermediate Risk Prostate Cancer with I-125 Permanent Interstitial Brachytherapy Monotherapy. A Review of the H Lee Moffitt Cancer Center Experience
    Torres-Roca, JF, Cantor, AB, Shukla, S, Montejo, ME, Friedland, J, Seigne, JD, Heysek, R, Me Marco, ML, Kelley, S, and Pow-Sang, J, ASTRO, Int J Radiat Oncol Biol Phys, 1/1/2004

Committees

  • member, NRG Cervix Committee 2019 - Present

Other Languages

  • Spanish

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: